The International Society of Glomerular Disease is pleased to welcome Barbara Gillespie, MD, MMS, FASN, into the advisory role of Chief Medical and Strategy Officer. In this capacity she will strengthen collaboration across the glomerular disease ecosystem to advance scientific and clinical development, novel therapies, and key ISGD initiatives, including Centers of Excellence, endpoint initiatives, and clinical trial programs.
Dr. Gillespie has collaborated with sponsors on clinical trial design and execution since beginning her career as a CRO nephrologist in 2006, leading CKD and ESRD trials across more than 20 indications, and will maintain her role as Therapeutic Head of Nephrology at Fortrea. As an Adjunct Professor in the Division of Nephrology and Hypertension at the University of North Carolina, she continues to care for patients and currently rounds in a local hemodialysis unit. Her work in glomerular disease spans Lupus Nephritis, IgA Nephropathy, FSGS, Primary Membranous Nephropathy, APOL1 Kidney Disease, Alport Syndrome, and Fabry Nephropathy with a strong focus on clinical trial endpoints. She serves on multiple national advisory and steering committees and previously served on the Board of Directors of the Kidney Health Initiative (2018–2023).
She can be reached at bgillespie@is-gd.org.
Tobias B. Huber, MD, FASN, President of ISGD, emphasizes the significance of this appointment: “Barbara combines exceptional scientific depth, strategic clarity, and a focus on patients with glomerular disease. Her ability to bridge industry, regulators, investigators, and patient communities will enhance and expand our ISGD leadership team.”
Dr. Gillespie in Hamburg for the 15th International Podocyte Conference (2025).
COMMENTS